Swedish e-pharmacy Apotea rang the bell at Nasdaq Stockholm on Dec. 6 to celebrate its initial public offering, marking the largest debut on Nasdaq's European markets in 2024 by market capitalization.

Apotea AB (publ) operates an online pharmacy in Sweden. The company offers products in the areas of allergy, face, baby, child and parent, bite and sting, preparedness, animal, fever and aches, cold, ...

Visit a quote page and your recently viewed tickers will be displayed here.

During operations, the RightPick system will be stationed at the end of a conveyor belt to receive and pick products from the SSI source tote, barcode scan if necessary, and place the product in the ...

Apotea’s Q4 2025 revenues grew by 7%, reaching 1,854 million SEK. Full-year revenue growth was 10.1%, totaling 7,203 million SEK. The stock rose 5.13% in pre-market trading following earnings release.

Exclusive content, detailed data sets, and best-in-class trade insights to rewrite your portfolio for tomorrow. Apotea is Sweden’s largest online pharmacy, trusted by over three million active ...

Apotea achieved 10.5% revenue growth in Q1 2025. The operating margin improved to 5.2%, reflecting better profitability. The stock price surged by 13.72% following the earnings announcement.

Earnings call Apotea delivered Q4 revenue of SEK 1,854m (+7% YoY), but profitability was weak with an EBIT margin of 1.3% due to intense campaign activity and ramp-up costs for the new Varberg ...

Net revenue for the second quarter increased by 9.9% (26.1) to SEK 1,826.2 million (1,661.1) and operating profit (EBIT) excluding items affecting comparability amounted to SEK 99.3 million (78.6), ...

Apotea AB ( (SE:APOTEA)) has provided an update. Apotea AB has scheduled the publication of its Q4 2025 year-end report for 4 February 2026 at 07:30 CET, followed by a webcast presentation at 09:30 ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.